Otsuka energizes IgA neuropathy space with new Phase 3 Voyxact data
BioSpace
By inhibiting the APRIL cascade, Otsuka Pharmaceuticals' Voyxact slowed kidney function decline in patients with IgAN, opening up a potential path for full approval while also reading through to Verte
pharminent
June 5, 2026 (Last updated: June 5, 2026)
BioSpace
By inhibiting the APRIL cascade, Otsuka Pharmaceuticals’ Voyxact slowed kidney function decline in patients with IgAN, opening up a potential path for full approval while also reading through to Verte